U.S. Markets close in 2 hrs 31 mins

ImmunoGen, Inc. (IMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.10+0.08 (+1.33%)
As of 1:29PM EDT. Market open.
People also watch
SGENIMMUEXELINCYCLDX

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451
United States
781-895-0600
http://www.immunogen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees308

Key Executives

NameTitlePayExercisedAge
Mr. Mark J. EnyedyChief Exec. Officer, Pres and Director568.98kN/A53
Mr. David B. JohnstonChief Financial Officer and Exec. VP279.44kN/A62
Dr. Richard J. Gregory Ph.D.Chief Scientific Officer and Exec. VP312.48kN/A59
Dr. Anna Berkenblit M.D., MM.ScChief Medical Officer and VP269.23kN/A47
Ms. Carol HausnerExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.